MYGN
Myriad Genetics, Inc.6.88
-0.11-1.57%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Q&A adds MRD metrics, ASP color
Q&A drilled into Precise MRD's alpha launch next week, revealing metrics like user experience, repeat orders, and volume to disclose from Q1—yet MolDX timing remains the wildcard, with zero revenue in 2026 guide. Management flagged a modest 1%-2% ASP headwind from payer mix, not rate erosion, using Q3/Q4 as baseline. Prenatal Q1 dips on comps but rebounds Q2 via focused sales team; Prolaris gains persist beyond easy comps. Sales org now channels prenatal and oncology separately for reach. No walk-backs, just execution color. Confident tone holds; watch MRD traction, prenatal rebuild.
Key Stats
Market Cap
641.31MP/E (TTM)
-Basic EPS (TTM)
-4.35Dividend Yield
0%Recent Filings
10-K
FY2025 results
Myriad Genetics posted FY2025 revenue of $824.5M, down 2% y/y, with volumes up 1% to 1.54M tests amid UnitedHealthcare's GeneSight coverage cut that slashed Mental Health revenue 15% despite 6% volume growth. Hereditary Cancer rose 2% on 7% volume gains, Prenatal gained 5% via higher pricing, yet Tumor Profiling dipped 3% post-EndoPredict divestiture. Q4 momentum faltered as impairments hit: $235M goodwill write-downs and $82M intangibles, triggered by market cap plunge and forecast cuts, yielding a $366M net loss. New $125M term debt bolsters liquidity to $225M total; covenants demand revenue ramps to $974M by 2029. R&D spend fell 6% to $107M amid lab transitions. Reimbursement volatility threatens quarterly flows.
8-K
Q4 revenue flat, guidance firm
Myriad Genetics reported Q4 2025 revenue of $209.8 million, flat year-over-year but up 4% excluding $8.1 million GeneSight coverage loss from UnitedHealthcare. Test volumes rose 2% to 382,000, driven by 9% growth in hereditary cancer and Prolaris. Q4 adjusted EBITDA hit $14.3 million. Company reiterates 2026 revenue guidance of $860-880 million.
8-K
Preliminary 2025 revenues $822-824M
Myriad Genetics reported preliminary 2025 revenues of $822-824 million, up from prior periods, with total test volumes hitting ~1.5 million—a 1% rise driven by 7% hereditary cancer growth and 6% mental health gains, yet 4% prenatal dip. It issued 2026 guidance: $860-880 million revenue, 68-69% adjusted gross margin, $37-49 million adjusted EBITDA. Figures remain preliminary, pending audit.
10-Q
Q3 FY2025 results
Myriad Genetics posted Q3 revenue of $205.7M, down 3.5% y/y from $213.3M yet stable q/q, with Hereditary Cancer up to $93.0M (45% of total) offsetting Pharmacogenomics weakness from UnitedHealthcare cuts. Gross margin held at 70.0%, but operating loss widened to $(23.3)M from $(20.0)M y/y on steady expenses; YTD net loss hit $358.0M versus $84.8M last year, driven by $316.7M goodwill/intangible impairments exceeding operating loss by >20% due to market cap decline and forecast revisions. Cash climbed to $145.4M on $125M term loan (10.8% rate, due 2030, $75M delayed draw available) netting $72.4M financing inflow, while ops used $8.8M and capex $10.9M left free cash flow negative (derived). Debt covenants met. Qui tam suits under False Claims Act loom.
8-K
Q3 revenue flat ex-headwinds
Myriad Genetics reported Q3 2025 revenue of $205.7 million, down 4% year-over-year but flat excluding $8.1 million headwinds from UnitedHealthcare's GeneSight coverage cut and EndoPredict divestiture. Hereditary cancer testing revenue rose 3% with 11% volume growth, while gross margin hit 69.9% and adjusted EBITDA $10.3 million. Strategic collaboration with SOPHiA GENETICS targets pharma liquid biopsy CDx services. Full-year 2025 guidance reiterated.
IPO
Website
Employees
Sector
Industry
DGX
Quest Diagnostics Incorporated
178.66-5.45
EXAS
Exact Sciences Corporation
101.76+0.02
GH
Guardant Health, Inc.
100.00-2.67
GNTLF
GENETIC TECHNOLOGIES
1.00+0.00
IDXG
Interpace Biosciences, Inc.
1.14-0.02
ILMN
Illumina, Inc.
131.56-3.36
IMDX
Insight Molecular Diagnostics I
5.10+0.08
MDXH
MDxHealth SA
3.36+0.05
MEHCQ
CHROME HLDG CO
3.50+0.00
TWST
Twist Bioscience Corporation
31.13+0.06